| Ytd | -48.08% | |
| 1y | -23.35% |
| Open | 10.59 | Prev Close | 10.61 | Low | 10.47 | High | 10.68 | Mkt Cap | 338.22M |
| Vol | 113.32K | Avg Vol | 301.62K | EPS | -3.01 | P/E | -3.51 | Forward P/E | -3.00 |
| Beta | 0.97 | Short Ratio | 5.28 | Inst. Own | 100.86% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 10.88 | 200-d Avg | 14.48 | 1yr Est | 43.55 |
Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(1.21) per share which missed the ana
Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage
Wells Fargo analyst Benjamin Burnett maintains Keros Therapeutics (NASDAQ:KROS) with a Overweight
On Wednesday, 311 stocks hit new 52-week lows.
On Tuesday, 647 companies set new 52-week lows.
On Monday, 369 companies set new 52-week lows.
On Tuesday, 386 stocks made new 52-week lows.
During the session on Thursday, 461 stocks hit new 52-week lows.